Spiriva Safety Debate Pits Clinical Study Results Against Meta-Analysis
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA also asks advisory panel to assess mixed efficacy results for BI's drug to reduce exacerbation of chronic obstructive pulmonary disease.